Norstella Executive and Leadership Team

Michael Gallup, the Chief Executive Officer at Norstella, directs the overarching strategic vision for the organization. By unifying diverse entities like Citeline and Evaluate, the Chief Executive Officer ensures seamless integration of scarce data assets to support pharmaceutical clients. This leadership role involves constant collaboration with the Board to refine long-term growth trajectories across global markets. Michael Gallup maintains a sharp focus on expanding the company's footprint in real-world data and machine learning applications. Through rigorous oversight of operational synergies, the Chief Executive Officer drives the mission of improving patient access to critical therapies. Gallup prioritizes the development of cutting-edge advisory services that empower life sciences companies to navigate complex commercial landscapes. By fostering a culture of innovation, the Chief Executive Officer secures the company's position as a premier intelligence provider in the pharmaceutical sector.

Daniel Tempesta, the Chief Financial Officer at Norstella, manages the fiscal health and capital allocation strategies for the entire enterprise. Overseeing global financial planning and analysis, the Chief Financial Officer ensures that investments in machine learning and predictive analytics align with corporate profitability targets. This role involves rigorous monitoring of revenue streams across all subsidiary organizations to maintain sustainable growth. Daniel Tempesta directs the financial reporting processes that provide transparency to stakeholders and investors. By optimizing cost structures and resource distribution, the Chief Financial Officer supports the company's ability to deliver high-value intelligence solutions. Tempesta also evaluates potential acquisitions and partnerships that enhance the breadth of expertise available to life sciences clients. Through disciplined financial management, the Chief Financial Officer strengthens the balance sheet, enabling the company to scale operations effectively while navigating the complexities of the drug development life cycle.

Elizabeth Addlesberger, the Chief Revenue Officer at Norstella, architects the global sales strategy and client engagement frameworks. Driving revenue growth across the entire portfolio, the Chief Revenue Officer ensures that life sciences clients receive tailored access to market-leading intelligence solutions. This leadership role involves aligning sales teams with the specific needs of pharmaceutical companies at every stage of the drug development process. Elizabeth Addlesberger monitors market trends to identify new opportunities for expanding the company's reach in North American and international territories. By implementing data-driven sales methodologies, the Chief Revenue Officer maximizes the impact of the company's advisory services. Addlesberger collaborates closely with product development teams to ensure that commercial offerings meet evolving industry demands. Through consistent focus on client success and retention, the Chief Revenue Officer secures long-term partnerships that solidify the company's market position as a critical resource for strategic decision-making.

Andy Augustine, the Chief Technology Officer at Norstella, leads the development and deployment of advanced technological infrastructure. Overseeing the integration of machine learning, predictive analytics, and real-world data platforms, the Chief Technology Officer ensures that the company remains at the forefront of pharmaceutical intelligence. This role involves architecting scalable systems that process vast amounts of scarce data to provide actionable insights for clients. Andy Augustine directs the engineering teams responsible for maintaining the security and reliability of the company's digital solutions. By fostering innovation in data processing, the Chief Technology Officer enables the organization to deliver cutting-edge tools that simplify complex drug development challenges. Augustine collaborates with other C-suite leaders to align technical capabilities with the broader business mission. Through continuous improvement of the technology stack, the Chief Technology Officer drives operational efficiency and enhances the value proposition for life sciences partners worldwide.

Joel Keefe, the Chief Revenue Officer, Mmit, Skipta, Panalgo, Rwd & Evidence Generation at Norstella, manages commercial growth specifically within the evidence generation and market access divisions. By focusing on the unique requirements of real-world data and evidence generation, the Chief Revenue Officer, Mmit, Skipta, Panalgo, Rwd & Evidence Generation ensures that clients leverage these assets to improve patient access. This role involves directing sales initiatives that highlight the value of Panalgo and MMIT solutions in the drug development life cycle. Joel Keefe coordinates with cross-functional teams to deliver integrated advisory services that address specific commercial hurdles. Through strategic market positioning, the Chief Revenue Officer, Mmit, Skipta, Panalgo, Rwd & Evidence Generation expands the adoption of evidence-based decision-making tools. Keefe drives revenue by demonstrating the tangible impact of these specialized solutions on pharmaceutical market performance and patient outcomes across diverse therapeutic areas.

Kevin D'Ambrosia, the Chief Revenue Officer, Heorand Rwe & Rwd & Skipta at Norstella, oversees revenue generation focused on health economics and outcomes research. By driving the adoption of real-world evidence solutions, the Chief Revenue Officer, Heorand Rwe & Rwd & Skipta ensures that pharmaceutical clients possess the data necessary to prove therapeutic value. This role involves managing client relationships that rely on Skipta and other specialized platforms to navigate complex regulatory and commercial environments. Kevin D'Ambrosia directs sales strategies that emphasize the importance of HEOR data in securing patient access. Through targeted outreach and consultative selling, the Chief Revenue Officer, Heorand Rwe & Rwd & Skipta expands the company's influence in the evidence-based medicine market. D'Ambrosia aligns commercial efforts with the broader mission of providing must-have answers for strategic decision-making, ultimately supporting the company's growth in the global life sciences intelligence sector.

Shrinal Patel, the Chief Medical Officer at Norstella, provides clinical expertise and scientific oversight for the company's intelligence solutions. By ensuring that data assets and advisory services remain grounded in medical accuracy, the Chief Medical Officer supports the development of high-quality insights for pharmaceutical clients. This role involves interpreting complex clinical data to guide strategic decision-making throughout the drug development life cycle. Shrinal Patel collaborates with technology and product teams to validate the clinical relevance of predictive analytics and real-world evidence. Through leadership in medical affairs, the Chief Medical Officer enhances the company's credibility as a trusted partner for life sciences organizations. Patel also engages with industry stakeholders to address emerging medical challenges and patient access barriers. By integrating clinical rigor into the company's offerings, the Chief Medical Officer ensures that all intelligence solutions effectively support the goal of improving patient health outcomes globally.